首頁 > 市場調查報告書 > 製藥

癌症

多發性骨髓瘤治療市場規模、佔有率和成長分析（按治療方法、給藥途徑、疾病類型、最終用戶和地區分類）—產業預測，2026-2033年

市場調查報告書

商品編碼

1898353

多發性骨髓瘤治療市場規模、佔有率和成長分析（按治療方法、給藥途徑、疾病類型、最終用戶和地區分類）—產業預測，2026-2033年

Multiple Myeloma Therapeutics Market Size, Share, and Growth Analysis, By Therapy Type (Chemotherapy, Targeted Therapy), By Route of Administration (Oral, Parenteral), By Disease Type, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球多發性骨髓瘤治療市場規模將達到 263.6 億美元，到 2025 年將達到 280.2 億美元，到 2033 年將達到 456.9 億美元，預測期（2026-2033 年）的複合年成長率為 6.3%。

由於多發性骨髓瘤這種危及生命的血液癌症的複雜性，以及對骨髓和漿細胞生成的嚴重影響，全球多發性骨髓瘤治療市場正經歷顯著成長。人口老化以及對該疾病分子機制的深入了解，都促進了這個市場的成長。科學技術的進步催生了針對惡性漿細胞的特化且強效的治療方法，從而改善了患者的治療效果。幹細胞移植、免疫調節藥物、蛋白酶體抑制劑、化療和單株抗體等治療策略是推動市場成長的關鍵因素。隨著製藥公司加強對創新治療方法和個人化醫療的投資，市場競爭異常激烈。這些公司積極合作，致力於開發療效較佳、副作用較少的新型治療方法，例如單株抗體和CAR-T細胞療法。

推動全球多發性骨髓瘤藥物市場發展的因素

全球多發性骨髓瘤治療市場的發展主要得益於新型先進治療方法的湧現。研究人員和製藥公司正積極開發創新治療方法，例如單株抗體、蛋白酶體抑制劑和免疫調節藥物（IMiDs），這些療法旨在靶向癌細胞，同時最大限度地減少對正常細胞的損傷。對這些突破性藥物的關注正在提高治療效果，從而改善患者的生存期和治療後的整體生活品質。這些進展不僅代表癌症治療的突破，也為與多發性骨髓瘤作鬥爭的患者帶來了希望，並體現了腫瘤治療的持續發展。

全球多發性骨髓瘤藥物市場受到抑制

儘管治療方案的進步改善了患者的預後，但某些治療方法的高成本仍然是一大障礙。許多多發性骨髓瘤患者由於經濟困難，尤其是在經濟資源匱乏或醫療資源不足的地區，難以獲得治療。這些經濟限制會阻礙創新療法的應用，最終阻礙市場成長。因此，這些重要治療方法的可負擔性和可近性仍然是必須解決的關鍵障礙，只有解決這些問題，更廣泛的患者群體才能受益於多發性骨髓瘤治療的最新進展。

全球多發性骨髓瘤藥物市場趨勢

全球多發性骨髓瘤治療市場正呈現出顯著的趨勢，即標靶治療和免疫療法的進步，這主要源自於對更有效、特異性的治療方法的需求。鑑於傳統化療在療效和副作用方面的局限性，製藥公司正在加速開發能夠精準靶向癌細胞並最大限度減少對健康組織損傷的新型治療方法。這包括開發單株抗體和其他標靶藥物，以抑制骨髓瘤細胞的生長和存活。此外，免疫療法，特別是CAR-T細胞療法的良好療效，凸顯了精準醫療的趨勢，有助於提高多發性骨髓瘤的治療效果和患者預後。

北美（治療方法、給藥途徑、疾病和最終用戶分類）
- 美國
- 加拿大
歐洲（治療方法、給藥途徑、疾病、最終使用者）
- 英國
- 德國
- 西班牙
- 法國
- 義大利
- 其他歐洲
亞太地區（按治療方法、給藥途徑、疾病和最終用戶分類）
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲（按治療方法、給藥途徑、疾病和最終用戶分類）
- 巴西
- 墨西哥
- 其他拉丁美洲
中東和非洲（按治療方法、給藥途徑、疾病和最終用戶分類）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭對手儀錶板

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）

主要企業簡介

F. Hoffmann-La Roche Ltd.
The following companies are listed for indicative purposes only. Similar information will be provided for each, with detailed financial data available exclusively for publicly listed companies.
Bristol Myers Squibb
Takeda Pharmaceutical Company Limited
Amgen Inc.
Sanofi SA
Johnson & Johnson
AbbVie Inc.
GlaxoSmithKline plc
Novartis AG
Pfizer Inc.
Karyopharm Therapeutics Inc.
Ono Pharmaceutical Co., Ltd.
Genmab A/S
Adaptive Biotechnologies Corporation
Legend Biotech Corporation
bluebird bio, Inc.
BeiGene, Ltd.
Merck & Co., Inc.
AstraZeneca plc
Bayer AG

結論和分析師建議

簡介目錄

Product Code: SQMIG35I2237

Global Multiple Myeloma Therapeutics Market size was valued at USD 26.36 Billion in 2024 and is poised to grow from USD 28.02 Billion in 2025 to USD 45.69 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).

The global multiple myeloma therapeutics market is experiencing significant growth, driven by the complexities of this life-threatening hematological cancer that affects bone marrow and plasma cell production. The rise in the aging population and increased understanding of the disease at a molecular level have contributed to this expansion. Enhanced scientific advancements are leading to the development of specialized and potent therapies targeting malignant plasma cells, thereby improving patient outcomes. Therapeutic strategies such as stem cell transplants, immunomodulatory drugs, proteasome inhibitors, chemotherapy, and monoclonal antibodies are crucial for market growth. The landscape is highly competitive as pharmaceutical companies invest in innovative treatments and personalized care, fostering collaborations that yield novel therapies like monoclonal antibodies and CAR-T cell therapies with improved efficacy and reduced side effects.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Myeloma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Myeloma Therapeutics Market Segments Analysis

Global Multiple Myeloma Therapeutics Market is segmented by Therapy Type, Route of Administration, Disease Type, End User and region. Based on Therapy Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunomodulating agents, Stem cell transplantation, Radiation therapy and Others. Based on Route of Administration, the market is segmented into Oral and Parenteral. Based on Disease Type, the market is segmented into Smouldering (Indolent) Multiple Myeloma, Active (Symptomatic) Multiple Myeloma, Solitary Plasmacytoma of the Bone, Extrameduallry Plasmacytoma, Light Chain Myeloma, Non-Secretory Myeloma, Rare Types of Myeloma and Others. Based on End User, the market is segmented into Hospitals & Clinics, Cancer Centers, Homecare settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiple Myeloma Therapeutics Market

The global multiple myeloma therapeutics market is significantly propelled by the emergence of novel and advanced treatment options. Researchers and pharmaceutical companies are actively developing innovative therapies, including monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs (IMiDs), which are designed to target cancer cells while minimizing harm to healthy cells. This focus on breakthrough medications has enhanced the efficacy of treatments, leading to improved patient survival rates and overall quality of life following therapy. Such advancements not only represent a leap in cancer treatment but also foster hope for patients battling multiple myeloma, reflecting the ongoing evolution of oncological care.

Restraints in the Global Multiple Myeloma Therapeutics Market

Despite advancements in therapeutic options that have enhanced patient outcomes, the high cost of certain treatments poses a significant barrier. Many patients encounter challenges in accessing multiple myeloma therapies due to affordability issues, particularly in regions with limited economic resources or inadequate healthcare access. This financial constraint can restrict the adoption of innovative treatments, ultimately impeding market growth. As a result, the affordability and accessibility of these vital therapies represent key obstacles that must be addressed to ensure a broader patient population benefits from the latest advancements in multiple myeloma treatment options.

Market Trends of the Global Multiple Myeloma Therapeutics Market

The Global Multiple Myeloma Therapeutics market is witnessing a significant trend toward the advancement of targeted therapies and immunotherapies, driven by the need for more effective and specific treatment options. As traditional chemotherapy has limitations in both efficacy and side effects, pharmaceutical companies are increasingly developing novel therapies that precisely target cancer cells while minimizing damage to healthy tissues. This includes the creation of monoclonal antibodies and other targeted agents that inhibit the growth and survival of myeloma cells. Furthermore, the promising results from immunotherapies, particularly CAR-T cell therapy, underscore a shift toward personalized medicine, enhancing treatment efficacy and patient outcomes in multiple myeloma management.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Patent Analysis
Clinical Trial
Pipeline Analysis

Global Multiple Myeloma Therapeutics Market Size by Type (2019-2032)

Market Overview
Chemotherapy
- Traditional chemotherapy
- Immunomodulating agents
- Proteasome inhibitors
- Histone Deacetylase (HDAC) inhibitors
- Monoclonal Antibodies
Targeted Therapy
Immunomodulating agents
Stem cell transplantation
Radiation therapy
Others

Global Multiple Myeloma Therapeutics Market Size by Route of Administration (2019-2032)

Market Overview
Oral
Parenteral

Global Multiple Myeloma Therapeutics Market Size by Disease Type (2019-2032)

Market Overview
Smouldering (Indolent) Multiple Myeloma
Active (Symptomatic) Multiple Myeloma
Solitary Plasmacytoma of the Bone
Extrameduallry Plasmacytoma
Light Chain Myeloma
Non-Secretory Myeloma
Rare Types of Myeloma
Others

Global Multiple Myeloma Therapeutics Market Size by End User (2019-2032)

Market Overview
Hospitals & Clinics
Cancer Centers
Homecare settings
Others

Global Multiple Myeloma Therapeutics Market Size (2019-2032)

North America (By Therapy Type, By Route of Administration, By Disease Type & By End User)
- US
- Canada
Europe (By Therapy Type, By Route of Administration, By Disease Type & By End User)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific (By Therapy Type, By Route of Administration, By Disease Type & By End User)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America (By Therapy Type, By Route of Administration, By Disease Type & By End User)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Therapy Type, By Route of Administration, By Disease Type & By End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Dashboard

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025

Key Company Profiles

F. Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio Overview
- Financial Overview
- Key Developments
The following companies are listed for indicative purposes only. Similar information will be provided for each, with detailed financial data available exclusively for publicly listed companies.
Bristol Myers Squibb
Takeda Pharmaceutical Company Limited
Amgen Inc.
Sanofi S.A.
Johnson & Johnson
AbbVie Inc.
GlaxoSmithKline plc
Novartis AG
Pfizer Inc.
Karyopharm Therapeutics Inc.
Ono Pharmaceutical Co., Ltd.
Genmab A/S
Adaptive Biotechnologies Corporation
Legend Biotech Corporation
bluebird bio, Inc.
BeiGene, Ltd.
Merck & Co., Inc.
AstraZeneca plc
Bayer AG